Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...

Novo Nordisk is doubling down on its investment in genetic medicine-based biotechs, inking a new collaboration with a lipid ...

Novo Nordisk (NVO) closed the latest trading day at $132.06, indicating a +0.05% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 0.29%.

The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.

Canada’s NanoVation Therapeutics has partnered with Novo Nordisk to advance genetic medicines for cardiometabolic and rare ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO ...